drugset
drugset / Trial / NCT06561048

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

NCT06561048 ↗

Phase 3 Recruiting 150 enrolled Corvus Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

A Phase 3, randomized, 2-arm, open-label, multicenter, stratified study of soquelitinib versus physician's choice standard of care (SOC) treatment (selected single agents) in participants with relapsed/refractory (R/R) peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), follicular helper T-cell lymphomas (FHTCLs), or systemic anaplastic large-cell lymphoma (sALCL).

Timeline

Start
2024-10-02
Primary completion
2027-11
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Belinostat Small molecule 1000 mg/m2 Intravenous
Comparator Pralatrexate Other / unclassified 30 mg/m2 Intravenous
Subject Soquelitinib Small molecule 200 mg Oral

Indications

Nodal T-follicular helper cell lymphoma, follicular type anaplastic large cell lymphoma angioimmunoblastic T-cell lymphoma peripheral T-cell lymphoma, not otherwise specified